A method of defining a standard reference sample for a whole traditional Chinese medicine, the method comprising: a) obtaining at least two specimens of the whole traditional Chinese medicine consisting of Panax quinquefolius, Panax ginseng, Curcuma spp., Ganoderma lucidum, Ganoderma sinense that have been authenticated as representing a positive control by qualitative profiling using an organoleptic examination; b) quantitatively profiling each of the at least two specimens that are authenticated as the positive control in step a) using High Performance Thin Layer Chromatography in combination of High-Performance Liquid Chromatography, Fourier Transform Infrared Spectroscopy and/or Gas-Liquid Chromatography and quantitatively profiling at least one of the at least two speciments using at least one biologic/genomic analysis selected from group consisting of proteomic assay, clinical trial, and DNA microarray to confirm positive authenticity of the specimens; c) blending at least two speciments that are authenticated as the positive control in step a) and confirmed in the step b) to form the standard reference sample; d) and creating a quantitative profile for the standard reference sample using High Performance Thin Layer Chromatography in combination of High-Performance Liquid Chromatography, Fourier Transform Infrared Spectroscopy and/or Gas-Liquid Chromatography and quantitatively profiling of the standard reference sample using at least one biologic/genomic analysis selected from group consisting of proteomic assay, clinical trial, and DNA microarray; wherein the quantitative profile for the standard reference sample defines the standard reference sample. a) obtaining at least two specimens of the whole traditional Chinese medicine consisting of Panax quinquefolius, Panax ginseng, Curcuma spp., Ganoderma lucidum, Ganoderma sinense that have been authenticated as representing a positive control by qualitative profiling using an organoleptic examination; b) quantitatively profiling each of the at least two specimens that are authenticated as the positive control in step a) using High Performance Thin Layer Chromatography in combination of High-Performance Liquid Chromatography, Fourier Transform Infrared Spectroscopy and/or Gas-Liquid Chromatography and quantitatively profiling at least one of the at least two speciments using at least one biologic/genomic analysis selected from group consisting of proteomic assay, clinical trial, and DNA microarray to confirm positive authenticity of the specimens; c) blending at least two speciments that are authenticated as the positive control in step a) and confirmed in the step b) to form the standard reference sample; d) and creating a quantitative profile for the standard reference sample using High Performance Thin Layer Chromatography in combination of High-Performance Liquid Chromatography, Fourier Transform Infrared Spectroscopy and/or Gas-Liquid Chromatography and quantitatively profiling of the standard reference sample using at least one biologic/genomic analysis selected from group consisting of proteomic assay, clinical trial, and DNA microarray; wherein the quantitative profile for the standard reference sample defines the standard reference sample.